Decrease of CA 19–9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer

Abstract

Chemotherapy with gemcitabine has been shown to be an effective regimen in advanced or metastatic pancreatic cancer with improvement of both quality of life and survival time. The response of the tumour marker CA 19-9 to chemotherapy with gemcitabine was studied in order to find out whether it is related to survival time of patients. Forty-three consecutive patients (median age 61 years, range 39-76 years; 20 males, 23 females) suffering from histologically proven locally advanced or metastatic pancreatic adenocarcinoma and a baseline Karnofsky-index > or = 60 were treated with gemcitabine in a dose of 1,000 mg/m(-2) weekly x 7 followed by 1 week of rest during the first cycle and thereafter 1,000 mg/m(-2) weekly x 3 followed by 1 week of rest until progression. In 36 of 43 patients serial measurements of CA 19-9 could be performed. Patients with a decrease of > 20% of the baseline CA 19-9 level after 8 weeks of treatment (n = 25) had a significantly better median survival than patients with a rise or a decrease 20% during the first weeks of chemotherapy with gemcitabine is associated with a better survival of patients with locally advanced or metastatic pancreatic cancer. Serial measurements of CA 19-9 are useful to decide whether further chemotherapy after the first weeks of treatment is indicated.

References 17

1. 1.

   Aapro M. S., Martin C., Hatty S. Gemcitabine--a safety review. Anticancer Drugs. 1998;9(3):191-201.

   Not in our library10.1097/00001813-199803000-00001

2. 2.

   Ahlgren J. D. Chemotherapy for pancreatic carcinoma. Cancer. 1996;78(3 Suppl):654-663.

   Not in our library10.1002/(sici)1097-0142(19960801)78:3<654::aid-cncr46>3.0.co;2-v

3. 3.

   Burris H. A., Moore M. J., Andersen J., Green M. R., Rothenberg M. L., Modiano M. R., Cripps M. C., Portenoy R. K., Storniolo A. M., Tarassoff P. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403-2413.

   Not in our library10.1200/jco.1997.15.6.2403

4. 4.
   Phase II study of gemcitabine in patients with advanced pancreatic cancer · 1996

   No notice
5. 5.

   Glenn J., Steinberg W. M., Kurtzman S. H., Steinberg S. M., Sindelar W. F. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol. 1988;6(3):462-468.

   Not in our library10.1200/jco.1988.6.3.462

6. 6.

   Gogas H., Lofts F. J., Evans T. R., Daryanani S., Mansi J. L. Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? Br J Cancer. 1998;77(2):325-328.

   Not in our library10.1038/bjc.1998.50

7. 7.

   Ishii H., Okada S., Nose H., Yoshimori M., Aoki K., Okusaka T. Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy. Pancreas. 1996;12(3):267-271.

   Not in our library10.1097/00006676-199604000-00009

8. 8.

   Katz A., Hanlon A., Lanciano R., Hoffman J., Coia L. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41(2):393-396.

   Not in our library10.1016/s0360-3016(98)00058-3

9. 9.

   Koprowski H., Steplewski Z., Mitchell K., Herlyn M., Herlyn D., Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979;5(6):957-971.

   Not in our library10.1007/bf01542654

10. 10.

    Lundin J., Roberts P. J., Kuusela P., Haglund C. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer. 1994;69(3):515-519.

    Not in our library10.1038/bjc.1994.93

11. 11.

    Okusaka T., Okada S., Sato T., Wakasugi H., Saisho H., Furuse J., Ishikawa O., Matsuno S., Yokoyama S. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer. Hepatogastroenterology. 1998;45(21):867-872.

    Not in our library

12. 12.

    Pleskow D. K., Berger H. J., Gyves J., Allen E., McLean A., Podolsky D. K. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med. 1989;110(9):704-709.

    Not in our library10.7326/0003-4819-110-9-704

13. 13.

    Rothenberg M. L., Abbruzzese J. L., Moore M., Portenoy R. K., Robertson J. M., Wanebo H. J. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer. 1996;78(3 Suppl):627-632.

    Not in our library10.1002/(sici)1097-0142(19960801)78:3<627::aid-cncr43>3.0.co;2-y

14. 14.

    Rothenberg M. L., Moore M. J., Cripps M. C., Andersen J. S., Portenoy R. K., Burris H. A., Green M. R., Tarassoff P. G., Brown T. D., Casper E. S. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 1996;7(4):347-353.

    Not in our library10.1093/oxfordjournals.annonc.a010600

15. 15.

    Safi F., Schlosser W., Falkenreck S., Beger H. G. Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterology. 1998;45(19):253-259.

    Not in our library

16. 16.

    Schnall S. F., Macdonald J. S. Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol. 1996;23(2):220-228.

    Not in our library

17. 17.

    Tian F., Appert H. E., Myles J., Howard J. M. Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg. 1992;215(4):350-355.

    Not in our library10.1097/00000658-199204000-00008

Cited by papers we hold 3

• CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials · 2005
  No notice
• Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer · 2005
  No notice
• Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine · 2003
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.